We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

CRSP CRISPR Therapeutics AG

-4.63 (-7.18%)
Last Updated: 12:58:52
Delayed by 15 minutes


Draw Mode:

Volume 7,179,849
Bid Price 59.93
Ask Price 59.94
News -
Day High 63.00


52 Week Range


Day Low 56.08
Share Name Share Symbol Market Stock Type
CRISPR Therapeutics AG CRSP NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-4.63 -7.18% 59.9061 12:58:52
Open Price Low Price High Price Close Price Previous Close
62.95 56.08 63.00 64.54
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
91,233 7,179,849 US$ 59.56 US$ 427,651,120 - 37.55 - 76.97
Last Trade Type Quantity Price Currency
12:58:52 1 US$ 59.9312 USD

CRISPR Therapeutics (CRSP) Options Flow Summary

Overall Flow


Net Premium


Calls / Puts


Buys / Sells




Sweeps Ratio


CRISPR Therapeutics AG Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
4.76B 79.43M - 1.2M -650.18M -8.19 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

CRISPR Therapeutics News

Date Time Source News Article
12/08/202315:11Dow Jones NewsBluebird Bio Shares Slide 41% on Black-Box Label, Higher..
12/08/202312:16Edgar (US Regulatory)Form 8-K - Current report
12/08/202311:52Business WireVertex and CRISPR Therapeutics Announce US FDA Approval of..
12/08/202310:46Dow Jones NewsCRISPR, Vertex Get FDA OK of Casgevy Gene Therapy in..
12/04/202315:26Edgar (US Regulatory)Form 8-K - Current report
12/04/202315:15GlobeNewswire Inc.CRISPR Therapeutics Announces Updates to Immuno-Oncology..
11/16/202306:21Edgar (US Regulatory)Form 8-K - Current report
11/16/202300:45Business Wire Vertex and CRISPR Therapeutics Announce Authorization of..
11/06/202315:42Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/06/202315:33Edgar (US Regulatory)Form 8-K - Current report
11/06/202315:15GlobeNewswire Inc.CRISPR Therapeutics Provides Business Update and Reports..
11/06/202304:01GlobeNewswire Inc.CRISPR Therapeutics Announces Preclinical Data at the..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No CRSP Message Board. Create One! See More Posts on CRSP Message Board See More Message Board Posts

Historical CRSP Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week69.1076.9756.0866.785,295,187-9.19-13.31%
1 Month52.0376.9748.550166.633,784,4347.8815.14%
3 Months50.3376.9737.5556.822,298,1259.5819.03%
6 Months61.7676.9737.5555.831,613,278-1.85-3.0%
1 Year49.2076.9737.5554.311,425,27510.7121.76%
3 Years154.18220.2137.5585.971,520,387-94.27-61.15%
5 Years35.93220.2121.6579.821,256,20323.9866.73%

CRISPR Therapeutics Description

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 |